Imaging News

In patients with persistent atrial fibrillation, a strategy of ablation based on MRI assessment of atrial fibrosis was not superior to pulmonary vein isolation for prevention of arrhythmia recurrence, researchers reported.

Healio and Cardiology Today have curated a list of the most-read cardiology news of August 2021.

Immediate angiography did not provide a survival benefit compared with a delayed or selective strategy in patients with out-of-hospital cardiac arrest without ST-segment elevation, according to results of the TOMAHAWK trial.

Adding fractional flow reserve assessment of all epicardial vessels at the time of diagnostic coronary angiography did not reduce costs or improve quality of life compared with angiography alone in patients with chest pain.

A strategy of screening first-degree relatives of patients with bicuspid aortic valves was cost-effective and cost-saving, researchers reported at the European Society of Cardiology Congress.

For patients with unstable angina or non-STEMI referred for coronary angiography, the use of fentanyl as an analgesic for chest pain slowed the absorption of ticagrelor, resulting in greater platelet reactivity compared with lignocaine.

CardioNXT announced it received marketing clearance from the FDA for its cardiac mapping platform for the treatment of arrhythmia disorders.

In a new study, young adults born preterm demonstrated increased extracellular volume fraction in the left ventricle compared with their term-born peers, which may underlie their diastolic functional impairments.

Acutus Medical announced that its suite of new algorithms for the mapping and ablation of complex atrial arrhythmias received FDA clearance and CE mark approval.

For patients with chest pain, there is no single imaging test that will provide the perfect diagnosis for all, according to a speaker at the American Society for Preventive Cardiology Congress on CVD Prevention.